연구동향 분석

Inflammatory Cytokine and Osmolarity Changes in the Tears of Dry Eye Patients Treated with Topical 1% Methylprednisolone

이지환 김태임 민경 김세경 김응권 2014년

논문상세정보
인용/피인용
' Inflammatory Cytokine and Osmolarity Changes in the Tears of Dry Eye Patients Treated with Topical 1% Methylprednisolone' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의학
  • cytokines
  • dryeyesyndrome
  • methylprednisolone
  • osmolarconcentration
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
7,774 0

0.0%

' Inflammatory Cytokine and Osmolarity Changes in the Tears of Dry Eye Patients Treated with Topical 1% Methylprednisolone' 의 참고문헌

  • Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group
    Sall K Ophthalmology 107 631-639 [2000]
  • Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome
    Marsh P Ophthalmology 106 811-816 [1999]
  • Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients
    Lee HK OPHTHALMOLOGY 113 198-205 [2006]
  • The pathology of dry eye
    Baudouin C. Surv Ophthalmol 45 Suppl 2 S211-S220 [2001]
  • The definition and classification of dry eye disease: report of the definition and classification Subcommittee of the International Dry Eye WorkShop (2007)
    Ocul Surf 5 75-92 [2007]
  • Tear osmolarity--a new gold standard?
    Farris RL Adv Exp Med Biol 350 495-503 [1994]
  • Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness
    Benelli U Cont Lens Anterior Eye 33 61-67 [2010]
  • Tear osmolarity as a biomarker for dry eye disease severity
    Suzuki M Invest Ophthalmol Vis Sci 51 4557-4561 [2010]
  • Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye
    Nichols JJ Invest Ophthalmol Vis Sci 47 1319-1328 [2006]
  • Tear cytokine profiles in dysfunctional tear syndrome
    Lam H Am J Ophthalmol 147 198-205 [2009]
  • Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells
    Li DQ Invest Ophthalmol Vis Sci 45 4302-4311 [2004]
  • Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes
    Lemp MA CLAO J 21 221-232 [1995]
  • Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma
    Lagu B Bioorg Med Chem Lett 17 4382-4386 [2007]
  • Kawasaki Disease: Laboratory Findings and an Immunopathogenesis on the Premise of a “Protein Homeostasis System”
    이경일 Yonsei Medical Journal 53 2 262-275 [2012]
  • Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes
    Liacini A Matrix Biol 21 251-262 [2002]
  • IL17: potential therapeutic target in Sjögren’s syndrome using adenovirus-mediated gene transfer
    Nguyen CQ Lab Invest 91 54-62 [2011]
  • Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome
    Yoon KC INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 51 2 643-650 [2010]
  • Efficacy of Combined 0.05% Cyclosporine and 1% Methylprednisolone Treatment for Chronic Dry Eye
    Byun YJ CORNEA 31 5 509-513 [2012]
  • Effectiveness of dry eye therapy under conditions of environmental stress
    Tomlinson A Curr Eye Res 38 229-236 [2013]
  • Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye
    De Paiva CS Exp Eye Res 83 526-535 [2006]
  • Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye
    Stern ME Invest Ophthalmol Vis Sci 43 2609-2614 [2002]
  • Changes in the tear film and ocular surface from dry eye syndrome
    Johnson ME Prog Retin Eye Res 23 449-474 [2004]
  • Analysis of inflammatory cytokines in the tears of dry eye patients
    Massingale ML Cornea 28 1023-1027 [2009]
  • An objective approach to dry eye disease severity
    Sullivan BD Invest Ophthalmol Vis Sci 51 6125-6130 [2010]